SciSparc Ltd. (SPRC) Stock Analysis
Educational signal · not a buy or sell recommendation · How to read this
P/E 0.05 means the share price is 0.05 times one year of earnings per share; the S&P 500 usually sits near 20-25. Beta 2.43: the stock has moved about 143% more than the S&P 500.
For informational purposes only. Not financial advice. Machine-generated analysis by Stock Expert AI — model gpt-4o-mini, generated Jun 15, 2026. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief. Data sources: Financial Modeling Prep, Yahoo Finance, SEC EDGAR
Quick AnswerSciSparc Ltd. (SPRC) trades at $4.95 with MoonshotScore 17/100 (Grade F). SciSparc Ltd. is a biotechnology company focused on developing cannabinoid-based medications for neurological disorders. Sector: Healthcare.
Price as of Sep 11, 2026 · Last analyzed: Jun 15, 2026Analyst Coverage for SPRC: SPRC does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates SPRC against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
SPRC: 1/3 scored disciplines lean bearish. Dominant signal: Ken Griffin bearish.
How is this calculated? →Strongest side: Valuation (6/10, Moderate). Weakest side: Growth Durability (0/10, Negative).
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Why this analysis is different
- A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
SciSparc Ltd. (SPRC) Healthcare & Pipeline Overview
SciSparc Ltd. specializes in cannabinoid-derived pharmaceuticals aimed at addressing unmet medical needs in neurological disorders, with a focus on innovative therapies for conditions like Tourette syndrome and Alzheimer's disease.
What Is the Investment Thesis for SPRC?
SciSparc Ltd. presents a unique investment thesis centered around its innovative pipeline of cannabinoid-based therapies for neurological disorders. The company's lead candidate, SCI-110, addresses multiple indications with high unmet needs, including Tourette syndrome and Alzheimer's disease, which collectively represent a market potential exceeding $10 billion. The ongoing Phase IIa clinical trial for SCI-110 is a critical milestone, with results expected in the next 12 months, potentially validating the drug's efficacy. Additionally, strategic partnerships with Procaps and The Israeli Medical Center for Alzheimer's enhance the company's development capabilities and market reach. However, the company faces significant risks typical of early-stage biotech firms, including funding challenges and regulatory hurdles. Monitoring clinical trial outcomes and financing activities will be essential for assessing the company's growth trajectory.
Based on FMP financials and quantitative analysis
SPRC Key Highlights
Market Cap of $0.000567 million, indicating a micro-cap status with high volatility.
- Profit Margin of -1422.8%, reflecting early-stage development costs without revenue generation.
- Gross Margin of 46.4%, indicating potential for profitability upon successful product commercialization.
- Beta of 2.43, suggesting higher volatility compared to the broader market.
- No dividend yield, consistent with early-stage biotech firms focused on reinvestment.
Who Are SPRC's Competitors?
SPRC is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | MoonshotScore |
|---|---|---|---|---|
| CRON Cronos Group Inc. | $3.16 | +0.16% | $1.18B | 905-pillar |
| ACB Aurora Cannabis Inc. | $3.73 | +0.13% | $231M | — |
| NVO Novo Nordisk A/S | $44.01 | -1.23% | $195B | 925-pillar |
| VRTX Vertex Pharmaceuticals Incorporated | $514.90 | +0.07% | $131B | 965-pillar |
| REGN Regeneron Pharmaceuticals, Inc. | $793.26 | -1.78% | $81.7B | 945-pillar |
| ARGX argenx SE | $984.04 | -1.82% | $61.2B | 975-pillar |
| UCBJY UCB S.A. | $117.06 | -1.42% | $44.6B | 679-signal |
| ALNY Alnylam Pharmaceuticals, Inc. | $247.51 | -4.07% | $33.1B | 895-pillar |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.
What Are SPRC's Key Strengths?
Innovative pipeline targeting unmet medical needs.
- Strategic partnerships enhancing development capabilities.
- Expertise in cannabinoid-based therapies.
What Are SPRC's Weaknesses?
Limited financial resources typical of micro-cap companies.
- High dependency on clinical trial outcomes.
- Small workforce may limit operational capacity.
What Could Drive SPRC Stock Higher?
SPRC catalyst: Results from the Phase IIa clinical trial for SCI-110 expected within the next 12 months.
- Collaboration with Procaps for the development and manufacturing of SCI-110 and CannAmide.
- Partnership with The Israeli Medical Center for Alzheimer's to evaluate SCI-110's effectiveness.
What Are the Key Risks for SPRC?
Financial-distress signal — its Altman Z-Score of -22.17 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- Significant funding risks due to the company's micro-cap status.
- Regulatory hurdles associated with clinical trials and drug approvals.
- Market volatility affecting stock performance and investor sentiment.
What Are the Growth Opportunities for SPRC?
- Growth opportunity 1: The global market for Tourette syndrome treatments is estimated to reach $1 billion by 2027, driven by increased awareness and diagnosis rates. SciSparc's SCI-110, targeting this condition, is well-positioned to capture market share if clinical trials demonstrate efficacy, with results expected within the next year.
- Growth opportunity 2: The Alzheimer's disease therapeutics market is projected to exceed $20 billion by 2026. SciSparc's collaboration with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa trial for SCI-110 could lead to significant advancements in treatment options, potentially positioning the company as a leader in this space.
- Growth opportunity 3: SCI-210's focus on autism spectrum disorder and epilepsy taps into a combined market estimated at $5 billion. With ongoing research and partnerships, SciSparc aims to develop effective therapies that address these critical conditions, enhancing its product portfolio and market presence.
- Growth opportunity 4: The partnership with Procaps for the commercial manufacturing of SCI-110 and CannAmide allows SciSparc to leverage established production capabilities, potentially reducing time-to-market and costs associated with drug development. This strategic alliance could facilitate faster commercialization of its products.
- Growth opportunity 5: As public and private sectors increasingly invest in cannabinoid research, SciSparc could benefit from additional funding opportunities and grants aimed at innovative healthcare solutions. This influx of capital could support further clinical trials and product development.
What Opportunities Does SPRC Have?
- Growing acceptance of cannabinoid therapies in mainstream medicine.
- Potential for significant market growth in targeted therapeutic areas.
- Increasing investment in biotechnology and cannabinoid research.
What Threats Does SPRC Face?
- Regulatory challenges in drug approval processes.
- Intense competition from established biotech firms.
- Market volatility affecting funding and stock performance.
What Are SPRC's Competitive Advantages?
- Focus on niche therapeutic areas with high unmet medical needs.
- Strategic partnerships that enhance research and development capabilities.
- Innovative approach to cannabinoid-based medications differentiating from traditional pharmaceuticals.
What Does SPRC Do?
Founded in 2004 as Therapix Biosciences Ltd., SciSparc Ltd. is a biotechnology company based in Tel Aviv, Israel, that focuses on the clinical development of cannabinoid-based medications. The company rebranded to SciSparc Ltd. in January 2021 to better reflect its commitment to pioneering cannabinoid therapies. With a small team of two employees, SciSparc is dedicated to addressing critical therapeutic areas through its innovative pipeline. The company’s lead product candidate, SCI-110, is currently under investigation for the treatment of Tourette syndrome, obstructive sleep apnea, and agitation associated with Alzheimer's disease. Additionally, SCI-160 is being developed to alleviate pain, while SCI-210 targets autism spectrum disorder and epilepsy. SciSparc has established strategic partnerships to enhance its research and development capabilities, including a collaboration with Procaps for the commercial manufacturing of SCI-110 and CannAmide, an oral palmitoylethanolamide. Furthermore, the company is working with the Sheba Fund for Health Services and Research to explore SCI-210's potential in managing status epilepticus and has partnered with The Israeli Medical Center for Alzheimer's to conduct a Phase IIa clinical trial for SCI-110. Through these collaborations, SciSparc aims to leverage its expertise in cannabinoid-based therapies to develop effective treatments for patients with significant unmet medical needs.
What Products and Services Does SPRC Offer?
- Develop cannabinoid-based pharmaceuticals targeting neurological disorders.
- Conduct clinical trials to evaluate the safety and efficacy of drug candidates.
- Collaborate with research institutions and pharmaceutical partners for product development.
- Focus on unmet medical needs in conditions such as Tourette syndrome and Alzheimer's disease.
- Engage in strategic partnerships to enhance manufacturing and commercialization efforts.
How Does SPRC Make Money?
- Generate revenue through the commercialization of successful drug candidates.
- Leverage partnerships for shared development costs and expertise.
- Seek funding through grants and investments to support research and clinical trials.
What Industry Does SPRC Operate In?
The biotechnology industry is characterized by rapid innovation and significant investment in drug development, particularly in the realm of cannabinoid-based therapies. The global cannabinoid market is projected to grow at a CAGR of over 20% through 2028, driven by increasing acceptance of cannabinoid products in medical applications. SciSparc Ltd. positions itself within this growing landscape, focusing on central nervous system disorders, an area with substantial unmet medical needs. The competitive landscape includes other biotech firms developing cannabinoid therapies, but SciSparc's targeted approach to specific neurological conditions may provide a competitive edge.
Who Are SPRC's Key Customers?
- Healthcare providers seeking innovative treatments for patients.
- Pharmaceutical partners interested in cannabinoid-based therapies.
- Investors looking for opportunities in biotechnology and healthcare sectors.
Research confidence
Enough evidence to be useful, with gaps worth knowing about.
- ● Scored on 100% of our measures
- ● Price is current
- ● Latest filing 135 days ago
- ● No analyst coverage
Why 17?
Measured against companies in the same sector. The figures below are the factor contributions the scoring engine itself produced.
What is helping
- +0.54 Enterprise value vs EBITDA (Valuation)
- +0.54 Enterprise value vs free cash flow (Valuation)
- +0.54 Price to book (Valuation)
What is holding it back
- -0.78 Operating margin (Business Quality)
- -0.78 Net margin (Business Quality)
- -0.78 Free cash flow yield (Business Quality)
Risk penalties applied
- -1.89 Bankruptcy-risk score in the distress zone
- -2.00 Loss-making with negative retained earnings
Contribution = how far the company sits from its sector on that measure, weighted by how much the pillar counts. Not investment advice. How the score is built →
MoonshotScore History
Recorded daily since 2026-08-23 · 19 snapshots
| 2026-08-23 | 45 |
| 2026-08-26 | 45 |
| 2026-08-29 | 45 |
| 2026-09-01 | 17 |
| 2026-09-04 | 17 |
| 2026-09-07 | 17 |
| 2026-09-10 | 17 |
What changed?
The grade moved from 45 to 17 (-28).
Over the same 18 days the stock moved -26.1%.
Company Profile
SciSparc Ltd. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Tel Aviv-Yafo, Israel.
SciSparc Ltd. Financial Trajectory
SciSparc Ltd. (SPRC) reported $395K in revenue for Q4 FY2025, a decline of 14.3% compared to the prior quarter. The company recorded a net loss of $2.9M, with diluted EPS of $-70.21. Revenue has contracted over three consecutive quarters, which investors in this unknown Healthcare stock should monitor closely. Across the four most recent quarters, SPRC averaged $-80.16 in diluted EPS.
How SciSparc Ltd. Is Valued
Relative to its peer group, SPRC's quantitative score of 17/100 is below the peer average of 89/100.
Financial Health
SciSparc Ltd.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -22.17 places it in the distress zone, a signal of elevated financial risk.
SPRC Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Innovative pipeline targeting unmet medical needs.
- Strategic partnerships enhancing development capabilities.
- Expertise in cannabinoid-based therapies.
- Upcoming: Results from the Phase IIa clinical trial for SCI-110 expected within the next 12 months.
Bear Case
- Limited financial resources typical of micro-cap companies.
- High dependency on clinical trial outcomes.
- Small workforce may limit operational capacity.
- Potential: Significant funding risks due to the company's micro-cap status.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · September 2026
Recent Quarterly Results
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q4 FY2025 | $395,000 | -$3M | -$70.21 |
| Q2 FY2025 | $461,000 | -$9M | -$161.28 |
| Q4 FY2024 | $466,000 | -$3M | -$12.63 |
| Q2 FY2024 | $840,000 | -$3M | -$76.50 |
Q4 FY2025 · filed 29 Apr 2026 · SEC EDGAR →
Based on FMP financials and quantitative analysis
SPRC Latest News
-
12 Health Care Stocks Moving In Wednesday's After-Market Session
benzinga · Sep 2, 2026
-
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
thenewswire.com · Sep 2, 2026
-
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation Covering SCI-110
benzinga · Sep 2, 2026
-
12 Health Care Stocks Moving In Monday's After-Market Session
benzinga · Aug 31, 2026
SPRC Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations collected by Financial Modeling Prep for SPRC.
Price Targets
Wall Street price target analysis for SPRC.
SPRC MoonshotScore
What does this score mean?
MoonshotScore is Stock Expert AI's proprietary 0-100 research rating, not a buy or sell recommendation. SPRC scores 17/100 (Grade F): the number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers.
Latest News
12 Health Care Stocks Moving In Wednesday's After-Market Session
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation for Adult Tourette Syndrome Drug; Engages Government and Public Affairs Firm RK Strategies
SciSparc Subsidiary NeuroThera Labs Pursues FDA Orphan Drug Designation Covering SCI-110
12 Health Care Stocks Moving In Monday's After-Market Session
Leadership: Oz Adler
CEO
Oz Adler has extensive experience in the biotechnology sector, having held various leadership roles throughout his career. He has a strong background in pharmaceutical development and strategic management, contributing to the growth and direction of SciSparc Ltd. under his leadership. Adler's educational credentials include degrees in relevant fields that bolster his expertise in managing biotech companies.
Track Record: Under Oz Adler's leadership, SciSparc has successfully transitioned from Therapix Biosciences Ltd. to SciSparc Ltd., focusing on cannabinoid therapies. His strategic decisions have led to the establishment of key partnerships that enhance the company's research capabilities and market positioning.
Common Questions About SPRC (Healthcare)
What does the AI Score mean for SPRC?
SPRC holds an AI Score of 17/100 (Grade: F). This is an educational research signal, not a buy or sell recommendation. The number comes from the five-pillar engine (business quality, financial safety, valuation, growth durability, momentum), re-ranked daily against sector peers. SciSparc Ltd. is a biotechnology company focused on developing cannabinoid-based medications for neurological disorders.
Is SPRC a good stock?
Stock Expert AI does not rate SPRC buy, sell or hold. SciSparc Ltd. carries a MoonshotScore of 17/100 on the five-pillar engine, a research rating against its peers. Whether it fits is your call: check what it sells, whether it earns, what the price assumes, and what would prove you wrong.
What are the key growth opportunities for SPRC in healthcare?
SciSparc Ltd. has several growth opportunities within the healthcare sector, particularly in the treatment of neurological disorders. The global market for Tourette syndrome treatments is expected to reach $1 billion by 2027, while the Alzheimer's disease therapeutics market is projected to exceed $20 billion by 2026.
What are the key factors to evaluate for SPRC?
SciSparc Ltd. (SPRC) holds a MoonshotScore of 17/100 (low). P/E: 0.05x vs the S&P 500's ~20-25x. Market Cap of $0.000567 million, indicating a micro-cap status with high volatility. Not financial advice.
How frequently does SPRC data refresh on this page?
SPRC's price was last updated on Sep 11, 2026 and refreshes on page view during U.S. market hours; the quote is a provider snapshot, not an exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven SPRC's recent stock price performance?
SciSparc Ltd. (SPRC) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative pipeline targeting unmet medical needs. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider SPRC overvalued or undervalued right now?
SciSparc Ltd. (SPRC) trades at 0.05x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
Can I buy fractional shares of SPRC?
Yes, most major brokerages offer fractional shares of SciSparc Ltd. (SPRC) with no minimum purchase requirement. This means you can invest any dollar amount regardless of the share price. Check your brokerage platform for specific terms, fees, and fractional share availability.
How can I track SPRC's earnings and financial reports?
SciSparc Ltd. (SPRC) reports quarterly earnings approximately 4-6 weeks after each fiscal quarter ends. You can track earnings dates, revenue and EPS estimates, and actual results on this page's Financials tab. Earnings surprises (beats or misses) often cause significant short-term price moves. Your brokerage can send alerts for SPRC earnings announcements.
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on available information as of June 2026.